CRIS Current Research Information System

LUATTI, SIMONA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.082
EU - Europa 1.476
AS - Asia 903
AF - Africa 97
SA - Sud America 8
OC - Oceania 3
Totale 4.569
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.078
GB - Regno Unito 420
VN - Vietnam 366
SE - Svezia 288
CN - Cina 239
IT - Italia 203
DE - Germania 179
SG - Singapore 166
UA - Ucraina 82
IN - India 79
FR - Francia 56
IE - Irlanda 55
RU - Federazione Russa 54
TG - Togo 35
EE - Estonia 34
ZA - Sudafrica 29
CH - Svizzera 28
JO - Giordania 27
BG - Bulgaria 26
BE - Belgio 16
CI - Costa d'Avorio 15
FI - Finlandia 12
NG - Nigeria 10
GR - Grecia 9
IR - Iran 8
SC - Seychelles 7
JP - Giappone 5
CA - Canada 4
BR - Brasile 3
CL - Cile 3
RO - Romania 3
TR - Turchia 3
CZ - Repubblica Ceca 2
HK - Hong Kong 2
ID - Indonesia 2
LB - Libano 2
NL - Olanda 2
NO - Norvegia 2
NZ - Nuova Zelanda 2
PL - Polonia 2
AE - Emirati Arabi Uniti 1
AT - Austria 1
AU - Australia 1
BO - Bolivia 1
EC - Ecuador 1
EG - Egitto 1
IL - Israele 1
KR - Corea 1
LT - Lituania 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 4.569
Salva come PNG Salva come JPEG
Città #
Southend 378
Fairfield 267
Chandler 247
Dong Ket 241
Ashburn 148
Singapore 144
Woodbridge 140
Seattle 127
Wilmington 127
Ann Arbor 119
Houston 117
Cambridge 97
Princeton 72
Dublin 55
Boardman 53
Jacksonville 52
Santa Clara 48
Nanjing 36
Lomé 35
Padova 34
Westminster 34
Beijing 30
Berlin 30
Turin 30
Amman 27
Bern 27
Bologna 27
Sofia 26
New York 25
Bremen 23
Florence 22
Saint Petersburg 19
Brussels 16
Jinan 16
Abidjan 15
Milan 14
Shenyang 14
Hebei 12
Helsinki 12
Nanchang 12
Hangzhou 11
Abeokuta 10
Castelfranco Emilia 10
San Diego 10
Falls Church 9
Redwood City 8
Tianjin 8
Des Moines 7
Guangzhou 7
Mahé 7
Mountain View 7
Mülheim 7
Haikou 6
Hyderabad 6
Jiaxing 6
Paris 6
Zhengzhou 6
Taiyuan 5
Taizhou 5
Tokyo 5
Verona 5
Changsha 4
Norwalk 4
Olalla 4
Washington 4
Wuhan 4
Andover 3
Boston 3
Bühl 3
Frankfurt am Main 3
Hefei 3
Kiev 3
Kunming 3
Los Angeles 3
Medford 3
Munich 3
Ningbo 3
Parma 3
Phoenix 3
Rome 3
Tappahannock 3
Ardabil 2
Auckland 2
Frankfurt Am Main 2
Henderson 2
Jakarta 2
Kuban 2
Lanzhou 2
Leawood 2
Mersin 2
Muizenberg 2
Plauen 2
Pune 2
San Francisco 2
San Venanzo 2
Shanghai 2
Shijiazhuang 2
São Paulo 2
Wenzhou 2
Winnipeg 2
Totale 3.222
Salva come PNG Salva come JPEG
Nome #
B-cell acute lymphoblastic leukemia as evolution of a 8p11 myeloproliferative syndrome with t(8;22)(p11;q11) and BCR-FGFR1 fusion gene. 226
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 217
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 205
Circulating calreticulin is increased in myelofibrosis: Correlation with interleukin-6 plasma levels, bone marrow fibrosis, and splenomegaly 198
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 177
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 174
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 174
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia 168
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 158
Identification of a novel t(1;9)(q11;q34) in acute myelocytic leukemia 153
Acute promyelocytic leukemia with amplification of PML-RARalpha rearrangement:clinical implications 153
Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities 148
Chronic myeloid leukemia: a prospective comparison of interphase fluorescence in situ hybridization and chromosome banding analysis for the definition of complete cytogenetic response, a study of the GIMEMA CML WP. 142
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 139
Mutations in JAK2 and Calreticulin genes are associated with specific alterations of the immune system in myelofibrosis 123
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 123
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 119
Crucial factors of the inflammatory microenvironment (IL-1β/ TNF-α/TIMP-1) promote the maintenance of the malignant hemopoietic clone of myelofibrosis: an in vitro study 116
Molecular and cytogenetic characterization of a new case of t(5;17)(q35;q21) variant acute promyelocytic leukemia 115
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 111
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 111
Ponatinib Is Well Tolerated and Active In Patients With Relapsed/Refractory Philadelphia Positive Acute Lymphoblastic Leukemia (PH+ ALL) and Advanced Phase Of Chronic Myelogenous Leukemia (CML) Harbouring T315I Mutation: The Bologna Experience 107
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 106
null 104
FGFR1 and KAT6A rearrangements in patients with hematological malignancies and chromosome 8p11 abnormalities: biological and clinical features 104
null 102
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 100
The long-term durability of cytogenetic response in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up 99
TP53 mutations are mutually exclusive with FLT3 and NPM mutations in AML patients and are strongly associated with complex karyotype and poor outcome 96
Ponatinib is well tolerated and active in patients with relapsed/refractory philadelphia positive leukemias: The Bologna experience 87
Results of high-dose imatinib mesylate in intermediate SOKAL risk chronic myeloid leukemia patients in early chronic phase: A phase II trial of the GIMEMA CML WP 82
null 81
null 77
t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities 64
Differences among young adults, adults and elderly chronic myeloid leukemia patients 60
Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up 51
Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain 48
Pancreatic enzymes elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 37
Erratum: Additional chromosomal abnormalities in Philadelphia-positive clone: Adverse prognostic influence on frontline imatinib therapy: A GIMEMA Working Party on CML analysis (Blood (2012) 120:4 (761-767)) 19
Totale 4.674
Salva come PNG Salva come JPEG
Categoria #
all - tutte 10.963
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.963
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020765 0 0 0 0 0 115 145 157 144 86 39 79
2020/2021729 97 54 20 15 13 32 5 37 60 23 35 338
2021/2022819 126 12 52 96 65 38 13 47 31 77 143 119
2022/2023953 110 159 57 119 62 75 22 52 148 20 89 40
2023/2024241 7 28 17 34 18 73 12 13 4 9 16 10
2024/2025368 31 107 57 55 117 1 0 0 0 0 0 0
Totale 4.674